Top

Published in:

01-11-2018 | Clinical study

Malignant melanoma in natalizumab recipients with MS

Published in: Reactions Weekly | Issue 1/2018

Excerpt

In patients with multiple sclerosis (MS), treatment with natalizumab appears to be associated with an increased risk of malignant melanoma (MM), according to the results of a study evaluating three databases reported in the Journal of the American Academy of Dermatology. …

Kelm RC, et al. Melanoma subsequent to natalizumab exposure: A report from the RADAR (Research on Adverse Drug events And Reports) Program. Journal of the American Academy of Dermatology : 2 Nov 2018. Available from: URL: http://doi.org/10.1016/j.jaad.2018.10.052

Title: Malignant melanoma in natalizumab recipients with MS
Publication date: 01-11-2018
Publisher: Springer International Publishing
Published in: Reactions Weekly / Issue 1/2018
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-018-54273-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Malignant melanoma in natalizumab recipients with MS

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2018

Erlotinib

Omeprazole

Multiple drugs

Cisplatin/paclitaxel

Denosumab

Multiple drugs